Tech Company Financing Transactions

Primmune Therapeutics Funding Round

Primmune Therapeutics closed a $27.4 million Series A funding round on 10/28/2020. Investors included CAM Capital, Polaris Partners and Biobrit.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

3210 Merryfield Row
San Diego, CA 92121
USA

Phone

Undisclosed

Website

www.primmunerx.com

Email Address

[email protected]

Overview

Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Charles McDermott

        

Vice President

Stephen Webber

        

VP - Bus. Development

Paulo Rangel

        

VP - R & D

James Appleman

        

Browse more venture capital transactions:

Prev: 10/28/2020: Nice Healthcare venture capital transaction
Next: 10/29/2020: WHOOP venture capital transaction

Share this article

Where The Data Comes From

We do our best to record every notable VC transaction. VC transactions on this site are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary